FDOPA Patterns in Adrenal Glands
Aurélie Moreau(Lyon 1 Université), C. Houzard(Hôpital Lyon Sud), Françoise Borson‐Chazot(Hospices Civils de Lyon), P. Combemale(Centre Léon Bérard), Anne‐Laure Giraudet(Centre de Recherche en Cancérologie de Lyon), Thomas Mognetti(Centre de Recherche en Cancérologie de Lyon), David Kryza(Laboratoire de Génie des Procédés Catalytiques), Francesco Giammarile(International Atomic Energy Agency), Jean‐Christophe Lifante(Lyon 1 Université), Claire Bournaud-Salinas
Cited by 4
Related Papers
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
|Neuroendocrinology|2017|495
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study
|Annals of Oncology|2015|257
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194